Modulating nitric oxide signaling in the CNS for Alzheimer’s disease therapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Thies W, Bleiler L. 2011 Alzheimer’s disease facts and figures. Alzheimers Dement.7(2),208–244 (2011).
  MedlineGoogle Scholar
• 2  Citron M. Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discov.9(5),387–398 (2010).▪ A comprehensive review on the development of disease-modifying approaches for Alzheimer’s disease (AD) treatment, with a focus on anti-amyloid strategies.
  Medline CASGoogle Scholar
• 3  Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu. Rev. Med.57,513–533 (2006).
  Medline CASGoogle Scholar
• 4  Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297(5580),353–356 (2002).
  Medline CASGoogle Scholar
• 5  Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat. Med.17(9),1060–1065 (2011).▪ A perspective summarized principal discoveries in AD research since 1960 and the sequence of steps in the discovery of disease-modifying treatments for AD.
  Medline CASGoogle Scholar
• 6  Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci.31,175–193 (2008).
  Medline CASGoogle Scholar
• 7  Jacobsen JS, Comery TA, Martone RL et al. Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade. Proc. Natl. Acad. Sci. USA105(25),8754–8759 (2008).
  Medline CASGoogle Scholar
• 8  Imbimbo BP, Peretto I. Semagacestat, a γ-secretase inhibitor for the potential treatment of Alzheimer’s disease. Curr. Opin. Investig. Drugs10(7),721–730 (2009).
  Medline CASGoogle Scholar
• 9  Martone RL, Zhou H, Atchison K et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer’s disease. J. Pharmacol. Exp. Ther.331(2),598–608 (2009).
  Medline CASGoogle Scholar
• 10  McLaurin J, Kierstead ME, Brown ME et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med.12(7),801–808 (2006).
  Medline CASGoogle Scholar
• 11  Gervais F, Paquette J, Morissette C et al. Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging28(4),537–547 (2007).
  Medline CASGoogle Scholar
• 12  Imbimbo BP. Why Did tarenflurbil fail in Alzheimer’s disease? J. Alzheimers Dis.17(4),757–760 (2009).
  Medline CASGoogle Scholar
• 13  Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed? Am. J. Geriatr. Pharmacother.7(3),167–185 (2009).
  Medline CASGoogle Scholar
• 14  Extance A. Alzheimer’s failure raises questions about disease-modifying strategies. Nat. Rev. Drug Discov.9(10),749–751 (2010).
  Medline CASGoogle Scholar
• 15  Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer’s disease? Biol. Psychiatry68(10),876–878 (2010).
  MedlineGoogle Scholar
• 16  Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol.9(7),702–716 (2010).
  Medline CASGoogle Scholar
• 17  Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-β peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci.25(29),6887–6897 (2005).▪▪ The paper reported that Aβ downregulates nitrous oxide (NO)/cGMP/PKG/CREB pathway, and proposed enhancement of NO/cGMP signaling might be a therapeutic approach for AD and another neurodegenerative diseases with elevated production of Aβ.
  Medline CASGoogle Scholar
• 18  Thatcher GR, Bennett BM, Reynolds JN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer’s disease. Curr. Alzheimer Res.2(2),171–182 (2005).▪▪ A comprehensive earlier review indicated that NO mimetics may provide a combined neuroprotective and cognition-enabling approach for AD therapy.
  Medline CASGoogle Scholar
• 19  Puzzo D, Staniszewski A, Deng SX et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer’s disease mouse model. J. Neurosci.29(25),8075–8086 (2009).
  Medline CASGoogle Scholar
• 20  Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol.76(2),126–152 (2005).
  Medline CASGoogle Scholar
• 21  Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci.8(10),766–775 (2007).▪ A comprehensive review of NO functions in CNS.
  Medline CASGoogle Scholar
• 22  Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog. Neurobiol.64(1),51–68 (2001).
  Medline CASGoogle Scholar
• 23  Hawkins RD. NO honey, I don’t remember. Neuron16(3),465–467 (1996).
  Medline CASGoogle Scholar
• 24  Garthwaite J. Glutamate, nitric oxide and cell–cell signalling in the nervous system. Trends Neurosci.14(2),60–67 (1991).
  Medline CASGoogle Scholar
• 25  Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci.19(23),10250–10261 (1999).
  Medline CASGoogle Scholar
• 26  Josselyn SA, Nguyen PV. CREB, synapses and memory disorders: past progress and future challenges. Curr. Drug Targets CNS Neurol. Disord.4(5),481–497 (2005).
  Medline CASGoogle Scholar
• 27  Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu. Rev. Neurosci.21,127–148 (1998).
  Medline CASGoogle Scholar
• 28  Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature361(6407),31–39 (1993).
  Medline CASGoogle Scholar
• 29  Arancio O, Kandel ER, Hawkins RD. Activity-dependent long-term enhancement of transmitter release by presynaptic 3´,5´-cyclic GMP in cultured hippocampal neurons. Nature376(6535),74–80 (1995).
  Medline CASGoogle Scholar
• 30  Arancio O, Kiebler M, Lee CJ et al. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell87(6),1025–1035 (1996).
  Medline CASGoogle Scholar
• 31  Arancio O, Antonova I, Gambaryan S et al. Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. J. Neurosci.21(1),143–149 (2001).
  Medline CASGoogle Scholar
• 32  Venturini G, Colasanti M, Persichini T et al. β-amyloid inhibits NOS activity by subtracting NADPH availability. FASEB J.16(14),1970–1972 (2002).
  Medline CASGoogle Scholar
• 33  Baltrons MA, Pedraza CE, Heneka MT, Garcia A. β-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol. Dis.10(2),139–149 (2002).
  Medline CASGoogle Scholar
• 34  Bonkale WL, Winblad B, Ravid R, Cowburn RF. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer’s disease. Neurosci. Lett.187(1),5–8 (1995).
  Medline CASGoogle Scholar
• 35  Suhara T, Magrane J, Rosen K et al. Aβ42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol. Aging24(3),437–451 (2003).
  Medline CASGoogle Scholar
• 36  Miller TW, Isenberg JS, Shih HB, Wang Y, Roberts DD. Amyloid-β inhibits NO-cGMP signaling in a CD36- and CD47-dependent manner. PLoS ONE5(12),e15686 (2011).
  Google Scholar
• 37  Greenberg ME, Ziff EB, Greene LA. Stimulation of neuronal acetylcholine receptors induces rapid gene transcription. Science234(4772),80–83 (1986).
  Medline CASGoogle Scholar
• 38  Montminy MR, Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature328(6126),175–178 (1987).
  Medline CASGoogle Scholar
• 39  Bito H, Deisseroth K, Tsien RW. CREB phosphorylation and dephosphorylation: a Ca²⁺- and stimulus duration-dependent switch for hippocampal gene expression. Cell87(7),1203–1214 (1996).
  Medline CASGoogle Scholar
• 40  Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol. Rev.89(1),121–145 (2009).
  Medline CASGoogle Scholar
• 41  Zheng Z, Sabirzhanov B, Keifer J. Oligomeric amyloid-β inhibits the proteolytic conversion of brain-derived neurotrophic factor (BDNF), AMPA receptor trafficking, and classical conditioning. J. Biol. Chem.285(45),34708–34717 (2010).
  Medline CASGoogle Scholar
• 42  Ma QL, Harris-White ME, Ubeda OJ et al. Evidence of Aβ- and transgene-dependent defects in ERK-CREB signaling in Alzheimer’s models. J. Neurochem.103(4),1594–1607 (2007).
  Medline CASGoogle Scholar
• 43  Espana J, Valero J, Minano-Molina AJ et al. β-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J. Neurosci.30(28),9402–9410 (2010).
  Medline CASGoogle Scholar
• 44  Saura CA, Valero J. The role of CREB signaling in Alzheimer’s disease and other cognitive disorders. Rev. Neurosci.22(2),153–169 (2011).
  Medline CASGoogle Scholar
• 45  Riccio A, Alvania RS, Lonze BE et al. A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons. Mol. Cell21(2),283–294 (2006).
  Medline CASGoogle Scholar
• 46  Puzzo D, Palmeri A, Arancio O. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer’s disease. Rev. Neurosci.17(5),497–523 (2006).
  Medline CASGoogle Scholar
• 47  Paul C, Stratil C, Hofmann F, Kleppisch T. cGMP-dependent protein kinase type I promotes CREB/CRE-mediated gene expression in neurons of the lateral amygdala. Neurosci. Lett.473(2),82–86 (2010).
  Medline CASGoogle Scholar
• 48  Zhuo M, Hu Y, Schultz C, Kandel ER, Hawkins RD. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature368(6472),635–639 (1994).
  Medline CASGoogle Scholar
• 49  Shahani N, Sawa A. Protein S-nitrosylation: role for nitric oxide signaling in neuronal death. Biochim. Biophys. Acta1820(6),736–742 (2012).
  Medline CASGoogle Scholar
• 50  Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev.87(1),315–424 (2007).
  Medline CASGoogle Scholar
• 51  Sultana R, Poon HF, Cai J et al. Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach. Neurobiol. Dis.22(1),76–87 (2006).
  Medline CASGoogle Scholar
• 52  Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J. Neurochem.85(6),1394–1401 (2003).
  Medline CASGoogle Scholar
• 53  Austin SA, Santhanam AV, Katusic ZS. Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ. Res.107(12),1498–1502 (2010).
  Medline CASGoogle Scholar
• 54  Chu Y, Heistad DD. No answer to Alzheimer’s disease? Circ. Res.107(12),1400–1402 (2010).
  Medline CASGoogle Scholar
• 55  Ciani E, Guidi S, Bartesaghi R, Contestabile A. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J. Neurochem.82(5),1282–1289 (2002).
  Medline CASGoogle Scholar
• 56  Ha KS, Kim KM, Kwon YG et al. Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J.17(9),1036–1047 (2003).
  Medline CASGoogle Scholar
• 57  Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med.330(9),613–622 (1994).
  Medline CASGoogle Scholar
• 58  Choi YB, Tenneti L, Le DA et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat. Neurosci.3(1),15–21 (2000).
  Medline CASGoogle Scholar
• 59  Melino G, Bernassola F, Knight RA, Corasaniti MT, Nistico G, Finazzi-Agro A. S-nitrosylation regulates apoptosis. Nature388(6641),432–433 (1997).
  Medline CASGoogle Scholar
• 60  Mannick JB, Schonhoff C, Papeta N et al.S-Nitrosylation of mitochondrial caspases. J. Cell. Biol.154(6),1111–1116 (2001).
  Medline CASGoogle Scholar
• 61  Tenneti L, D’Emilia DM, Lipton SA. Suppression of neuronal apoptosis by S-nitrosylation of caspases. Neurosci. Lett.236(3),139–142 (1997).
  Medline CASGoogle Scholar
• 62  Zhou P, Qian L, Iadecola C. Nitric oxide inhibits caspase activation and apoptotic morphology but does not rescue neuronal death. J. Cereb. Blood Flow Metab.25(3),348–357 (2005).
  Medline CASGoogle Scholar
• 63  Fahnestock M, Marchese M, Head E et al. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol. Aging33(3),546–554 (2010).
  MedlineGoogle Scholar
• 64  Lazarov O, Robinson J, Tang YP et al. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell120(5),701–713 (2005).
  Medline CASGoogle Scholar
• 65  Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science298(5594),789–791 (2002).
  Medline CASGoogle Scholar
• 66  Domek-Lopacinska KU, Strosznajder JB. Cyclic GMP and nitric oxide synthase in aging and Alzheimer’s disease. Mol. Neurobiol.41(2–3),129–137 (2010).
  Medline CASGoogle Scholar
• 67  Thatcher GR, Bennett BM, Dringenberg HC, Reynolds JN. Novel nitrates as NO mimetics directed at Alzheimer’s disease. J. Alzheimers Dis.6(6 Suppl.),S75–84 (2004).
  Medline CASGoogle Scholar
• 68  Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GRJ. Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester. Neuropsychopharmacology32(3),505–513 (2007).
  Medline CASGoogle Scholar
• 69  Wirtz-Brugger F, Giovanni A. Guanosine 3´,5´-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and β-amyloid: protective effects of propentofylline. Neuroscience99(4),737–750 (2000).
  Medline CASGoogle Scholar
• 70  Paris D, Town T, Parker T, Humphrey J, Mullan M. β-amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents. Ann. NY. Acad. Sci.903,446–450 (2000).
  Medline CASGoogle Scholar
• 71  Reynolds JN, Bennett BM, Boegman RJ et al. Neuroprotection against ischemic brain injury conferred by a novel nitrate ester. Bioorg. Med. Chem. Lett.12(20),2863–2866 (2002).
  Medline CASGoogle Scholar
• 72  Smith S, Dringenberg HC, Bennett BM, Thatcher GR, Reynolds JN. A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze. Neuroreport11(17),3883–3886 (2000).
  Medline CASGoogle Scholar
• 73  Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem.51(3),347–372 (2008).
  Medline CASGoogle Scholar
• 74  DiFabio J, Ji Y, Vasiliou V, Thatcher GRJ, Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol. Pharmacol.64(5),1109–1116 (2003).
  Medline CASGoogle Scholar
• 75  D’Souza Y, Ji Y, Bennett B. Effect of overexpression of human aldehyde dehydrogenase 2 in LLC-PK1 cells on glyceryl trinitrate biotransformation and cGMP accumulation. Br. J. Pharmacol.168(4),978–987 (2013).
  MedlineGoogle Scholar
• 76  Thatcher GRJ, Nicolescu AC, Bennett BM, Toader V. Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radic. Biol. Med.37(8),1122–1143 (2004).
  Medline CASGoogle Scholar
• 77  Lundberg JO, Gladwin MT, Ahluwalia A et al. Nitrate and nitrite in biology, nutrition and therapeutics. Nat. Chem. Biol.5(12),865–869 (2009).
  Medline CASGoogle Scholar
• 78  Harkany T, Abraham I, Timmerman W et al. β-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci.12(8),2735–2745 (2000).
  Medline CASGoogle Scholar
• 79  Louzada PR, Paula Lima AC, Mendonca-Silva DL, Noel F, De Mello FG, Ferreira ST. Taurine prevents the neurotoxicity of β-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer’s disease and other neurological disorders. FASEB J.18(3),511–518 (2004).
  Medline CASGoogle Scholar
• 80  Lin X, Jun-Tian Z. Neuroprotection by D-securinine against neurotoxicity induced by β-amyloid (25–35). Neurol. Res.26(7),792–796 (2004).
  MedlineGoogle Scholar
• 81  Lee BY, Ban JY, Seong YH. Chronic stimulation of GABA_A receptor with muscimol reduces amyloid beta protein (25–35)-induced neurotoxicity in cultured rat cortical cells. Neurosci. Res.52(4),347–356 (2005).
  Medline CASGoogle Scholar
• 82  Marcade M, Bourdin J, Loiseau N et al. Etazolate, a neuroprotective drug linking GABA_A receptor pharmacology to amyloid precursor protein processing. J. Neurochem.106(1),392–404 (2008).
  Medline CASGoogle Scholar
• 83  Limon A, Reyes-Ruiz JM, Miledi R. Loss of functional GABA_A receptors in the Alzheimer diseased brain. Proc. Natl. Acad. Sci. USA109(25),10071–10076 (2012).
  Medline CASGoogle Scholar
• 84  Vellas B, Sol O, Snyder PJ et al. EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr. Alzheimer Res.8(2),203–212 (2011).
  Medline CASGoogle Scholar
• 85  Nelson RM, Hainsworth AH, Lambert DG et al. Neuroprotective efficacy of AR-A008055, a clomethiazole analogue, in a global model of acute ischaemic stroke and its effect on ischaemia-induced glutamate and GABA efflux in vitro. Neuropharmacology41(2),159–166 (2001).
  Medline CASGoogle Scholar
• 86  Green AR, Hainsworth AH, Misra A et al. The interaction of AR-A008055 and its enantiomers with the GABA_A receptor complex and their sedative, muscle relaxant and anticonvulsant activity. Neuropharmacology41(2),167–174 (2001).
  Medline CASGoogle Scholar
• 87  Colado MI, O’Shea E, Esteban B, Green AR. Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA (‘ecstasy’)-induced neurodegeneration in rat brain. Psychopharmacology (Berl.)157(1),82–88 (2001).
  Medline CASGoogle Scholar
• 88  Harmon D, Coleman E, Marshall C, Lan W, Shorten G. The effect of clomethiazole on plasma concentrations of interleukin-6, -8, -1β, tumor necrosis factor-α, and neutrophil adhesion molecule expression during experimental extracorporeal circulation. Anesth. Analg.97(1),13–18 (2003).
  Medline CASGoogle Scholar
• 89  Clarkson AN, Liu H, Rahman R, Jackson DM, Appleton I, Kerr DS. Clomethiazole: mechanisms underlying lasting neuroprotection following hypoxia-ischemia. FASEB J.19(8),1036–1038 (2005).
  Medline CASGoogle Scholar
• 90  Wilby MJ, Hutchinson PJ. The pharmacology of chlormethiazole: a potential neuroprotective agent? CNS Drug Rev.10(4),281–294 (2004).
  Medline CASGoogle Scholar
• 91  Clarkson AN, Clarkson J, Jackson DM, Sammut IA. Mitochondrial involvement in transhemispheric diaschisis following hypoxia-ischemia: clomethiazole-mediated amelioration. Neuroscience144(2),547–561 (2007).
  Medline CASGoogle Scholar
• 92  Gilby KL, Sydserff SG, Robertson HA. Differential neuroprotective effects for three GABA-potentiating compounds in a model of hypoxia-ischemia. Brain Res.1035(2),196–205 (2005).
  Medline CASGoogle Scholar
• 93  Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology39(9),1483–1494 (2000).
  Medline CASGoogle Scholar
• 94  Shi JQ, Shen W, Chen J et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res.1368,239–247 (2011).
  Medline CASGoogle Scholar
• 95  Alvarez A, Cacabelos R, Sanpedro C, Garcia-Fantini M, Aleixandre M. Serum TNF-α levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging28(4),533–536 (2007).
  Medline CASGoogle Scholar
• 96  McAlpine FE, Lee JK, Harms AS et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis.34(1),163–177 (2009).
  Medline CASGoogle Scholar
• 97  Abdul-Hay S, Schiefer IT, Chandrasena RE et al. NO-SSRIs: nitric oxide chimera drugs incorporating a selective serotonin reuptake inhibitor. ACS Med. Chem. Lett.2(9),656–661 (2011).
  Medline CASGoogle Scholar
• 98  Caraci F, Copani A, Nicoletti F, Drago F. Depression and Alzheimer’s disease: neurobiological links and common pharmacological targets. Eur. J. Pharmacol.626(1),64–71 (2010).
  Medline CASGoogle Scholar
• 99  Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J. Major depression, cognitive dysfunction and Alzheimer’s disease: is there a link? Eur. J. Pharmacol.626(1),72–82 (2010).
  Medline CASGoogle Scholar
• 100  Qin Z, Luo J, VandeVrede L et al. Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. J. Med. Chem.55(15),6784–6801 (2012).
  Medline CASGoogle Scholar
• 101  Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ. The significance of neuroinflammation in understanding Alzheimer’s disease. J. Neural. Transm.113(11),1685–1695 (2006).
  Medline CASGoogle Scholar
• 102  Arnaud L, Robakis NK, Figueiredo-Pereira ME. It may take inflammation, phosphorylation and ubiquitination to ‘tangle’ in Alzheimer’s disease. Neurodegener. Dis.3(6),313–319 (2006).
  MedlineGoogle Scholar
• 103  Lleo A, Galea E, Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell. Mol. Life Sci.64(11),1403–1418 (2007).
  Medline CASGoogle Scholar
• 104  Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature414(6860),212–216 (2001).
  Medline CASGoogle Scholar
• 105  Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J. Neurosci.20(15),5709–5714 (2000).
  Medline CASGoogle Scholar
• 106  Jantzen PT, Connor KE, DiCarlo G et al. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci.22(6),2246–2254 (2002).
  Medline CASGoogle Scholar
• 107  Yan Q, Zhang J, Liu H et al. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer’s disease. J. Neurosci.23(20),7504–7509 (2003).
  Medline CASGoogle Scholar
• 108  Sastre M, Dewachter I, Rossner S et al. Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ. Proc. Natl. Acad. Sci. USA103(2),443–448 (2006).
  Medline CASGoogle Scholar
• 109  Zhou Y, Su Y, Li B et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science302(5648),1215–1217 (2003).
  Medline CASGoogle Scholar
• 110  You X, Zhang YW, Chen Y et al. Retinoid X receptor-α mediates (R)-flurbiprofen’s effect on the levels of Alzheimer’s β-amyloid. J. Neurochem111(1),142–149 (2009).
  Medline CASGoogle Scholar
• 111  Abdul-Hay SO, Edirisinghe P, Thatcher GR. Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels. J. Neurochem.111(3),683–695 (2009).
  Medline CASGoogle Scholar
• 112  Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GR. NO-flurbiprofen reduces amyloid-β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J. Neurochem.111(3),766-776 (2009).
  Medline CASGoogle Scholar
• 113  Schiefer IT, Abdul-Hay S, Wang H, Vanni M, Qin Z, Thatcher GR. Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J. Med. Chem.54(7),2293–2306 (2011).
  Medline CASGoogle Scholar
• 114  Kukar TL, Ladd TB, Bann MA et al. Substrate-targeting γ-secretase modulators. Nature453(7197),925–929 (2008).
  Medline CASGoogle Scholar
• 115  Beher D, Clarke EE, Wrigley JD et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem.279(42),43419–43426 (2004).
  Medline CASGoogle Scholar
• 116  Lleo A, Berezovska O, Herl L et al. Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nat. Med.10(10),1065–1066 (2004).
  Medline CASGoogle Scholar
• 117  Choi SH, Aid S, Caracciolo L et al. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J. Neurochem.124(1),59–68 (2013).
  Medline CASGoogle Scholar
• 118  James DS. The multisystem adverse effects of NSAID therapy. J. Am. Osteopath. Assoc.99(11 Suppl.),S1–S7 (1999).
  CASGoogle Scholar
• 119  Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin. Arthritis Rheum.32(3 Suppl. 1),25–32 (2002).
  Medline CASGoogle Scholar
• 120  Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA289(21),2819–2826 (2003).
  Medline CASGoogle Scholar
• 121  Aisen PS, Thal LJ, Ferris SH et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr. Alzheimer Res.5(1),73–82 (2008).
  Medline CASGoogle Scholar
• 122  Soininen H, West C, Robbins J, Niculescu L. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.23(1),8–21 (2007).
  Medline CASGoogle Scholar
• 123  Kukar T, Murphy MP, Eriksen JL et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nat. Med.11(5),545–550 (2005).
  Medline CASGoogle Scholar
• 124  Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA302(23),2557–2564 (2009).
  Medline CASGoogle Scholar
• 125  Marder K. Tarenflurbil in patients with mild Alzheimer’s disease. Curr. Neurol. Neurosci. Rep.10(5),336–337 (2010).
  MedlineGoogle Scholar
• 126  Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res. Ther.10Suppl 2,S4 (2008).
  MedlineGoogle Scholar
• 127  Calatayud S, Barrachina D, Esplugues JV. Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc. Res. Tech.53(5),325–335 (2001).
  Medline CASGoogle Scholar
• 128  Koc Kucukguzel SG. Medicinal chemistry and anti-inflammatory activity of nitric oxide-releasing NSAI drugs. Mini-Rev. Med. Chem.9(5),611–619 (2009).
  MedlineGoogle Scholar
• 129  Velazquez CA, Chen QH, Citro ML, Keefer LK, Knaus EE. Second-generation aspirin and indomethacin prodrugs possessing an O²-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem.51(6),1954–1961 (2008).
  Medline CASGoogle Scholar
• 130  de Carvalho PS, Marostica M, Gambero A, Pedrazzoli J Jr. Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivative containing a benzofuroxan moiety. Eur. J. Med. Chem.45(6),2489–2493 (2010).
  MedlineGoogle Scholar
• 131  Huang Z, Velazquez CA, Abdellatif KR et al. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies. J. Med. Chem.54(5),1356–1364 (2011).
  Medline CASGoogle Scholar
• 132  Bandarage UK, Chen L, Fang X et al. Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem.43(21),4005–4016 (2000).
  Medline CASGoogle Scholar
• 133  Bolla M, Almirante N, Benedini F. Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top Med. Chem.5(7),707–720 (2005).
  Medline CASGoogle Scholar
• 134  Ongini E, Bolla M. Nitric oxide based nonsteroidal anti-inflammatory agents. Drug Discov. Today3,395–400 (2006).
  Google Scholar
• 135  Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ 42 in vivo. J. Clin. Invest.112(3),440–449 (2003).
  Medline CASGoogle Scholar
• 136  Wallace JL, Muscara MN, de Nucci G et al. Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1´-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-prop enoic acid 4-nitrooxy butyl ester]. J. Pharmacol. Exp. Ther.309(2),626–633 (2004).
  Medline CASGoogle Scholar
• 137  van Groen T, Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res. Brain Res. Rev.48(2),370–378 (2005).
  Medline CASGoogle Scholar
• 138  Prosperi C, Scali C, Barba M et al. Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Aβ_1–42-induced brain inflammation and neuronal damage in the rat. Int. J. Immunopathol. Pharmacol.17(3),317–330 (2004).
  Medline CASGoogle Scholar
• 139  Christensen DD. Changing the course of Alzheimer’s disease: anti-amyloid disease-modifying treatments on the horizon. Prim. Care Companion J. Clin. Psychiatry9(1),32–41 (2007).
  MedlineGoogle Scholar
• 140  Peretto I, Radaelli S, Parini C et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of β-amyloid_1–42 secretion. J. Med. Chem.48(18),5705–5720 (2005).
  Medline CASGoogle Scholar
• 141  Imbimbo BP, Giardino L, Sivilia S et al. CHF5074, a novel γ-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer’s disease. J. Alzheimers Dis.20(1),159–173 (2010).
  Medline CASGoogle Scholar
• 142  Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer’s disease. Arch. Pharm. Res.33(10),1539–1556 (2010).
  Medline CASGoogle Scholar
• 143  Ballard CG. Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibition. Eur. Neurol.47(1),64–70 (2002).
  Medline CASGoogle Scholar
• 144  Kopf SR, Benton RS, Kalfin R, Giovannini MG, Pepeu G. NO synthesis inhibition decreases cortical ACh release and impairs retention of a conditioned response. Brain Res.894(1),141–144 (2001).
  Medline CASGoogle Scholar
• 145  Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann. Pharmacother.28(6),744–751 (1994).
  Medline CASGoogle Scholar
• 146  Fang L, Appenroth D, Decker M et al. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem.51(4),713–716 (2008).
  Medline CASGoogle Scholar
• 147  Fang L, Appenroth D, Decker M et al. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J. Med. Chem.51(24),7666–7669 (2008).
  Medline CASGoogle Scholar
• 148  Gracon SI, Knapp MJ, Berghoff WG et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord.12(2),93–101 (1998).
  Medline CASGoogle Scholar
• 149  Futter LE, al-Swayeh OA, Moore PK. A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br. J. Pharmacol.132(1),10–12 (2001).
  Medline CASGoogle Scholar
• 150  Chen Y, Sun J, Fang L et al. Tacrine–ferulic acid–nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J. Med. Chem.55(9),4309–4321 (2012).
  Medline CASGoogle Scholar
• 151  Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov.5(9),755–768 (2006).
  Medline CASGoogle Scholar
• 152  Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ. Res.97(7),618–628 (2005).
  MedlineGoogle Scholar
• 153  Li Y, Zhang D, Jin W et al. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J. Clin. Invest.116(2),506–511 (2006).
  Medline CASGoogle Scholar
• 154  Dikalov S, Fink B, Skatchkov M, Stalleicken D, Bassenge E. Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance. J. Pharmacol. Exp. Ther.286(2),938–944 (1998).
  Medline CASGoogle Scholar
• 155  Hoenicka M, Becker EM, Apeler H et al. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J. Mol. Med. (Berl.)77(1),14–23 (1999).
  Medline CASGoogle Scholar
• 156  Artz JD, Toader V, Zavorin SI, Bennett BM, Thatcher GR. In vitro activation of soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors and NO mimetics. Biochemistry40(31),9256–9264 (2001).
  Medline CASGoogle Scholar
• 157  Russwurm M, Mergia E, Mullershausen F, Koesling D. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J. Biol. Chem.277(28),24883–24888 (2002).
  Medline CASGoogle Scholar
• 158  Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol.54(6),962–967 (1998).
  Medline CASGoogle Scholar
• 159  Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol. Pharmacol.63(6),1322–1328 (2003).
  Medline CASGoogle Scholar
• 160  Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY, Fu WM. Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. Eur. J. Neurosci.21(6),1679–1688 (2005).
  MedlineGoogle Scholar
• 161  Chien WL, Liang KC, Fu WM. Enhancement of active shuttle avoidance response by the NO-cGMP-PKG activator YC-1. Eur. J. Pharmacol.590(1–3),233–240 (2008).
  Medline CASGoogle Scholar
• 162  Yang X, Wang Y, Luo J, Liu S, Yang Z. Protective effects of YC-1 against glutamate induced PC12 cell apoptosis. Cell Mol. Neurobiol.31(2),303–311 (2011).
  Medline CASGoogle Scholar
• 163  Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem.76,481–511 (2007).
  Medline CASGoogle Scholar
• 164  Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev.58(3),488–520 (2006).
  Medline CASGoogle Scholar
• 165  Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl.)202(1–3),419–443 (2009).
  Medline CASGoogle Scholar
• 166  Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov.5(8),660–670 (2006).
  Medline CASGoogle Scholar
• 167  Bales KR, Plath N, Svenstrup N, Menniti FS. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease. Top. Med. Chem.6,57–59 (2010).
  Google Scholar
• 168  Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann. Pharmacother.39(7–8),1286–1295 (2005).
  Medline CASGoogle Scholar
• 169  Devan BD, Sierra-Mercado D, Jr., Jimenez M et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol. Biochem. Behav.79(4),691–699 (2004).
  Medline CASGoogle Scholar
• 170  Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl.)196(4),643–648 (2008).
  Medline CASGoogle Scholar
• 171  Prickaerts J, van Staveren WC, Sik A et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience113(2),351–361 (2002).
  Medline CASGoogle Scholar
• 172  Prickaerts J, Sik A, van Staveren WC et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem. Int.45(6),915–928 (2004).
  Medline CASGoogle Scholar
• 173  Cuadrado-Tejedor M, Hervias I, Ricobaraza A et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer’s disease. Br. J. Pharmacol.164(8),2029–2041 (2011).
  Medline CASGoogle Scholar
• 174  Orejana L, Barros-Minones L, Jordan J, Puerta E, Aguirre N. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol. Aging33(3), 625 e611–e620 (2012).
  Google Scholar
• 175  Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav. Brain Res.240,11–20 (2013).
  Medline CASGoogle Scholar
• 176  Fiorito J, Saeed F, Zhang H et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer’s disease. Eur. J. Med. Chem.60,285-294 (2013).
  Medline CASGoogle Scholar
• 177  Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem.273(25),15559–15564 (1998).
  Medline CASGoogle Scholar
• 178  Andreeva SG, Dikkes P, Epstein PM, Rosenberg PA. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J. Neurosci.21(22),9068–9076 (2001).
  Medline CASGoogle Scholar
• 179  van Staveren WC, Glick J, Markerink-van Ittersum M et al. Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J. Neurocytol.31(8–9),729–741 (2002).
  Medline CASGoogle Scholar
• 180  Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, de Vente J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer’s disease human brains. Eur. J. Neurosci.25(11),3332–3338 (2007).
  MedlineGoogle Scholar
• 181  Menniti F, Kleiman R, Schmidt C. PDE9A-mediated regulation of cGMP: impact on synaptic plasticity. Schizophrenia Res.102,38–39 (2008).
  Google Scholar
• 182  Schmidt CJ, Harms J, Tingley FD et al. PDE9A-mediated regulation of cGMP: developing a biomarker for a novel therapy for Alzheimer’s disease. Alzheimers Dement.5(4),P331 (2009).
  Google Scholar
• 183  Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol.68(6),1775–1781 (2005).
  Medline CASGoogle Scholar
• 184  van der Staay FJ, Rutten K, Barfacker L et al. The novel selective PDE9 inhibitor BAY 73–6691 improves learning and memory in rodents. Neuropharmacology55(5),908–918 (2008).
  Medline CASGoogle Scholar
• 185  Verhoest PR, Fonseca KR, Hou X et al. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyr an-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J. Med. Chem.55(21),9045–9054 (2012).
  Medline CASGoogle Scholar
• 186  Hutson PH, Finger EN, Magliaro BC et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-py ran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology61(4),665–676 (2011).
  Medline CASGoogle Scholar
• 187  Meng F, Hou J, Shao YX et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J. Med. Chem.55(19),8549–8558 (2012).
  Medline CASGoogle Scholar
• 188  Vardigan JD, Converso A, Hutson PH, Uslaner JM. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J. Neurogenet.25(4),120–126 (2011).
  Medline CASGoogle Scholar
• 189  Nicholas T, Evans R, Styren S et al. PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: translation from non-clinical species to healthy human volunteers. Alzheimers Dement.5(4),P330–P331 (2009).
  Google Scholar
• 190  Nicholas T, Le V, Qiu R et al. Safety and pharmacokinetics of PF-04447943, a PDE9A inhibitor, in single and multiple dose Phase I studies in healthy volunteers. Alzheimers Dement.6,S135 (2010).
  MedlineGoogle Scholar
• 191  Schwam E, Evans R, Nicholas T et al. PF-04447943: a Phase II controlled clinical trial of a selective PDE9A inhbitor in Alzheimer’s disease. Alzheimers Dement.7(4),S695 (2011).
  Google Scholar
• 192  Wager TT, Chandrasekaran RY, Hou X et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci.1(6),420–434 (2010).
  Medline CASGoogle Scholar
• 193  Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci.1(6),435–449 (2010).
  Medline CASGoogle Scholar